Skip to content

XENON PHARMACEUTICALS INC.: 10-Q filed 2017-05-09

What XENON PHARMACEUTICALS INC. reported in its quarterly report filed 2017-05-09 (fiscal Q1 2017): 25 published measures, 54 facts as tagged in accession 0001564590-17-009917.

This filing

Form
10-Q (quarterly report)
Filed
2017-05-09
Fiscal period
fiscal Q1 2017
Accession
0001564590-17-009917 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All XENON PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-03-3160,786,000USD
At 2016-12-3167,487,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-03-313,591,000USD
At 2016-12-313,586,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-03-3157,195,000USD
At 2016-12-3163,901,000USD
At 2015-12-3161,034,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-03-3120,160,000USD
At 2016-12-3117,095,000USD
At 2016-03-3156,064,000USD
At 2015-12-3158,651,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-7,517,000USD90
2016-01-01 to 2016-12-31-22,997,000USD366
2016-01-01 to 2016-03-31-3,263,000USD91

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-03-31137,000USD90
2016-01-01 to 2016-03-3183,000USD91

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2017-01-01 to 2017-03-3116,000USD90
2016-01-01 to 2016-03-31601,000USD91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-03-31-150,201,000USD
At 2016-12-31-142,681,000USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2017-01-01 to 2017-03-3117,946,209shares90
2016-01-01 to 2016-03-3114,394,000shares91

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2017-01-01 to 2017-03-3117,974,469shares90
2016-01-01 to 2016-03-3114,394,000shares91

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-0.42USD/shares90
2016-01-01 to 2016-03-31-0.23USD/shares91

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-0.43USD/shares90
2016-01-01 to 2016-03-31-0.23USD/shares91

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-03-311,376,000USD
At 2016-12-311,404,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-03-31478,000USD90
2016-01-01 to 2016-03-31592,000USD91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-7,987,000USD90
2016-01-01 to 2016-03-31-5,658,000USD91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-03-3159,141,000USD
At 2016-12-3165,675,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2017-03-31189,000USD
At 2016-12-31200,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-01-01 to 2017-03-318,003,000USD90
2016-01-01 to 2016-03-316,259,000USD91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-01-01 to 2017-03-315,903,000USD90
2016-01-01 to 2016-03-314,364,000USD91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-03-3117,996,680shares
At 2016-12-3117,930,590shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-03-31-990,000USD
At 2016-12-31-990,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-03-31925,000USD
At 2016-12-311,329,000USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-7,517,000USD90
2016-01-01 to 2016-03-31-3,263,000USD91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-01-01 to 2017-03-312,100,000USD90
2016-01-01 to 2016-03-311,895,000USD91

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-11,000USD90
2016-01-01 to 2016-03-3160,000USD91

Inspect the source

Entity
XENON PHARMACEUTICALS INC. / CIK 0001582313
Captured
2026-09-20T09:22:52.756Z
SEC response SHA-256
192f372ec04a5f134b187ed4baddde08f5cf5af14daba171e6067f98261efde5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001582313.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))